Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Areti Sofogianni, Athanasios Filippidis, Lampros Chrysavgis, et al.
World Journal of Hepatology (2020) Vol. 12, Iss. 8, pp. 493-505
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra, Tao Wang, Kishore M. Gadde, et al.
Diabetes Care (2021) Vol. 44, Iss. 6, pp. 1433-1442
Open Access | Times Cited: 233
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, et al.
Clinical Science (2022) Vol. 136, Iss. 18, pp. 1347-1366
Open Access | Times Cited: 178
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 97
Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1
Ameng Shi, Ting Li, Ying Zheng, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 96
Diabetes medications and risk of HCC
Maria Corina Plaz Torres, Ariel Jaffe, Rachel J. Perry, et al.
Hepatology (2022) Vol. 76, Iss. 6, pp. 1880-1897
Open Access | Times Cited: 60
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al-Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 10
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Joanna Michałowska, Ewa Miller‐Kasprzak, Paweł Bogdański
Nutrients (2021) Vol. 13, Iss. 2, pp. 351-351
Open Access | Times Cited: 49
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
V. A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines (2022) Vol. 10, Iss. 2, pp. 274-274
Open Access | Times Cited: 37
The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
Ana G. Petrovic, Dunja Igrec, Karla Rožac, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 6, pp. 4544-4556
Open Access | Times Cited: 22
Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype
Alan J. Sinclair, Daniel Pennells, Ahmed H. Abdelhafiz
Aging Clinical and Experimental Research (2022) Vol. 34, Iss. 9, pp. 1949-1967
Open Access | Times Cited: 28
Metabolic Impact of Frailty Changes Diabetes Trajectory
Alan J. Sinclair, Ahmed H. Abdelhafiz
Metabolites (2023) Vol. 13, Iss. 2, pp. 295-295
Open Access | Times Cited: 16
Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis
Omar E Hegazi, Samer O Alalalmeh, Moyad Shahwan, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 545-561
Open Access | Times Cited: 4
Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
Anqi Lin, Yanxi Ding, Zhengrui Li, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Exploring the Putative Involvement of MALAT1 in Mediating the Beneficial Effect of Exendin-4 on Oleic Acid-Induced Lipid Accumulation in HepG2 Cells
Olfa Khalifa, Sama Ayoub, Abdelilah Arredouani
Biomedicines (2025) Vol. 13, Iss. 2, pp. 370-370
Open Access
The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health
Mohamad Al Qassab, M.A. Mneimneh, Ahmad Jradi, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 285-285
Open Access
Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective
Poonam Yadav, Amit Khurana, Jasvinder Singh Bhatti, et al.
Pharmacological Research (2022) Vol. 184, pp. 106426-106426
Closed Access | Times Cited: 13
Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
Daniela Maria Tănase, Evelina Maria Gosav, Daniela Petrov, et al.
Diagnostics (2021) Vol. 11, Iss. 11, pp. 2053-2053
Open Access | Times Cited: 17
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
Lampros Chrysavgis, Spyridon Kazanas, Konstantina Bafa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3832-3832
Open Access | Times Cited: 2
Glucagon-like Peptide-1 Receptor Agonists
Ja Young Jeon, Hae Jin Kim
Stroke revisited (2021), pp. 167-177
Closed Access | Times Cited: 15
Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism
Khaoula Errafii‬, Olfa Khalifa, Neyla S. Al-Akl, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1020-1020
Open Access | Times Cited: 11
Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
Maja Cigrovski Berković, Tanja Režić, Ines Bilić-Ćurčić, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 20, pp. 6759-6768
Open Access | Times Cited: 8
Exendin-4-induced reduction of steatosis in HepG2 cells implicates upregulation of essential lipid metabolism genes via modulation of MALAT1
Olfa Khalifa, Sama Ayoub, Abdelilah Arredouani
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials
Hao Wang, Qianqian Ma, Youpeng Chen, et al.
Obesity Reviews (2024) Vol. 25, Iss. 6
Open Access | Times Cited: 1
Histological and immunohistochemical study of the effect of liraglutide in experimental model of non-alcoholic fatty liver disease
Mai Salah Nour, Zeinab Abd El-Hay Sakara, Nawal Awad Hasanin, et al.
Egyptian Journal of Basic and Applied Sciences (2023) Vol. 10, Iss. 1, pp. 342-357
Open Access | Times Cited: 2
Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people
Demelza Emmerton, Ahmed H. Abdelhafiz
Hospital Practice (2021) Vol. 49, Iss. 3, pp. 164-175
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top